A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.

A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.
复制标题

一项针对组织学侵袭性非霍奇金淋巴瘤患者的 CHOP 与每周多药治疗方案 (PACEBOM) 的随机英国国家淋巴瘤研究试验。

DOI：
--
复制
发表时间：
2000
期刊：
Annals of Oncology
影响因子：
50.5
通讯作者：
W. Gregory
W. Gregory
中科院分区：
医学1区
文献类型：
--
作者：
D. Linch;P. Smith;B. Hancock;P. Hoskin;D. Cunningham;A. Newland;D. Milligan;P. A. Stevenson;J. Wood;K. Maclennan;B. Vaughan;G. Vaughan;W. Gregory

文献摘要

被引文献

相似文献

背景 1987 年至 1991 年间，英国国家淋巴瘤调查将 459 名具有大细胞成分的非霍奇金淋巴瘤患者随机分配至 CHOP 或 PACEBOM 方案。 患者和方法 根据工作方案，本试验纳入了 459 名符合条件的患者，其中 401 名患有弥漫性大细胞淋巴瘤，58 名患有弥漫性混合细胞淋巴瘤。 226 名患者被随机分配接受 CHOP，233 名患者被随机分配接受 PACEBOM。试验的两个组在所有潜在的预后因素方面都得到了很好的平衡。 结果 PACEBOM 的完全缓解率为 64%，CHOP 的完全缓解率为 57% (NS)。 8 年时，PACEBOM 组的精算原因特异性生存率 (CSS) 为 59%，而 CHOP 组为 49%（P = 0.09）。 PACEBOM 组中年龄 < 50 岁的患者的 CSS 和总生存率均显着改善 (P = 0.002)，并且 IV 期疾病的 CSS 也显着改善 (P = 0.02)。 结论 该试验的成熟数据表明，含依托泊苷的多药每周治疗方案可能优于 CHOP。
BACKGROUND Between 1987 and 1991, the British National Lymphoma Investigation randomized 459 patients with non-Hodgkin's lymphoma with a large-cell component to either CHOP or the PACEBOM regimen. PATIENTS AND METHODS Four hundred fifty-nine eligible patients were included in this trial, four hundred one with diffuse large-cell lymphoma and fifty-eight with diffuse mixed-cell lymphoma according to the Working Formulation. Two hundred twenty-six patients were randomized to receive CHOP and two hundred thirty-three to receive PACEBOM. The two arms of the trial were well balanced for all potential prognostic factors. RESULTS The complete remission rate with PACEBOM was 64% and with CHOP 57% (NS). At eight years, the actuarial cause specific survival (CSS) in the PACEBOM arm is 59% compared to 49% in the CHOP arm (P = 0.09). Patients < 50 years of age fared significantly better in the PACEBOM arm both for CSS and overall survival (P = 0.002) and the CSS was also significantly improved in stage IV disease (P = 0.02). CONCLUSIONS The mature data from this trial suggest that an etoposide-containing multi-agent weekly regimen can be superior to CHOP.